


# Reference Data

(Consolidated Financial Results for FY2012)



Daiichi-Sankyo

May 13, 2013

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

# MEMO

(This page is intentionally left blank)

# Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Management / Financial Indicators	P8
8.	Capital Expenditure and Depreciation Expenses	P8
9.	Consolidated Balance Sheets	P9
10.	Consolidated Statements of Cash Flow	P11
11.	Summary of Product Outlines	P12
12.	Major R&D Pipeline (Innovative pharmaceuticals)	P13

Supplemental Information

Historical Data

## 1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			FY2012				FY2013			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to sales	Forecast	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>242.6</b>	<b>+4.7%</b>	<b>100%</b>	<b>241.6</b>	<b>+7.7%</b>	<b>100%</b>	<b>261.5</b>	<b>+8.8%</b>	<b>100%</b>	<b>252.2</b>	<b>+4.1%</b>	<b>100%</b>	<b>997.9</b>	<b>59.2</b>	<b>+6.3%</b>	<b>100%</b>	<b>1,080.0</b>	<b>82.1</b>	<b>+8.2%</b>
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%	33%	83.4	+22.6%	31%	313.7	45.0	+16.8%	33%	355.0	41.3	+13.2%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%	67%	168.8	-3.1%	69%	684.2	14.1	+2.1%	67%	725.0	40.8	+6.0%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%	64%	161.8	-3.6%	58%	583.7	11.8	+2.1%	57%	615.0	31.3	+5.4%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%	20%	51.2	-8.9%	18%	183.0	-2.0	-1.1%	17%	187.0	4.0	+2.2%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%	11%	27.2	+2.7%	10%	96.8	1.1	+1.1%		not disclosed		
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%	16%	40.7	+17.0%	14%	143.7	4.7	+3.4%		not disclosed		
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%	17%	42.7	-15.2%	16%	160.2	8.0	+5.3%		not disclosed		
<b>Operating Income</b>	<b>13%</b>	<b>32.5</b>	<b>-25.2%</b>	<b>10%</b>	<b>24.6</b>	<b>+31.2%</b>	<b>14%</b>	<b>36.5</b>	<b>+22.9%</b>	<b>3%</b>	<b>7.0</b>	<b>+10.2%</b>	<b>10%</b>	<b>100.5</b>	<b>2.3</b>	<b>+2.4%</b>	<b>10%</b>	<b>110.0</b>	<b>9.5</b>	<b>+9.4%</b>
Non-operating income / expenses		8.3			-15.5			9.4			-3.5			-1.4	20.6			0.0	1.4	
Non-operating income		10.3			-5.3			8.1			4.5			17.6	7.6			not disclosed		
Non-operating expenses		2.0			10.2			-1.2			8.0			19.0	-13.0			not disclosed		
<b>Ordinary Income</b>	<b>17%</b>	<b>40.8</b>	<b>-9.0%</b>	<b>4%</b>	<b>9.0</b>	<b>-58.0%</b>	<b>18%</b>	<b>45.8</b>	<b>+128.3%</b>	<b>1%</b>	<b>3.5</b>	<b>-</b>	<b>10%</b>	<b>99.1</b>	<b>22.9</b>	<b>+30.1%</b>	<b>10%</b>	<b>110.0</b>	<b>10.9</b>	<b>+10.9%</b>
Extraordinary income / losses		0.6			-5.2			-5.7			3.3			-7.1	35.2			5.0	12.1	
Extraordinary income		2.0			0.5			0.7			8.9			12.1	-2.7			not disclosed		
Extraordinary losses		1.5			5.7			6.4			5.7			19.2	-37.9			not disclosed		
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-	3%	6.7	-	9%	92.1	58.2	+171.5%	11%	115.0	22.9	+24.9%
Income taxes / minority interests		21.0			-0.1			13.0			-8.4			25.5	1.9			47.0	21.5	
Income taxes		16.8			3.0			10.2			-6.0			23.9	-15.9			not disclosed		
Minority interests		4.2			-3.1			2.8			-2.4			1.6	17.8			not disclosed		
<b>Net Income</b>	<b>8%</b>	<b>20.4</b>	<b>-19.4%</b>	<b>2%</b>	<b>4.0</b>	<b>-66.3%</b>	<b>10%</b>	<b>27.1</b>	<b>-</b>	<b>6%</b>	<b>15.1</b>	<b>-</b>	<b>7%</b>	<b>66.6</b>	<b>56.2</b>	<b>+541.6%</b>	<b>6%</b>	<b>68.0</b>	<b>1.4</b>	<b>+2.1%</b>
Effective tax rate		41%			78%			25%			-90%			26%						
Overseas sales ratio results		54%			48%			44%			49%			49%						

### Notes to FY2012 Q4 Results Year-on-Year Comparisons

Net Sales	Nexium +17.7, Memary +14.0, Olmesartan +9.1, Ranbaxy +9.9, Welchol +6.3, Ranmark +4.4, Prasugrel alliance revenue +3.5 Mevalotin -6.1, Luitpold -6.1, Levofloxacin export, royalty, etc -3.1
SG&A expenses	R&D: Currency impact (appreciation of JPY to USD, EUR, and INR) +2.0    Other: Currency impact (appreciation of JPY to USD, EUR, and INR) -7.0
Non-operating items	"Gain on valuation of derivatives" and "Currency loss" of Ranbaxy +20.9
Extraordinary losses	FY2011 Q4: Provision for settlement expenses of Ranbaxy
Income Taxes	FY2011 Q4: Tax rate worsened by special factors; Reversal in deferred tax asset following the cut in income tax rate in Japan FY2012 Q4: Tax rate improved by deferred tax asset since accumulated losses were cleared

### Notes to FY2013 Forecast Year-on-Year Comparisons

Net Sales	Japan Company +37.5, Currency impact +67.0 (appreciation of JPY to USD, EUR +36.0, appreciation of JPY to INR +31.0) Overseas businesses -11.0
Cost of Sales	Change of products mix (+)
SG&A expenses	Currency impact (+)

## 2. Currency Rate

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2012		FY2013
	Results	Results	Results	Results	Results	YoY	Forecast
USD/JPY (average)	80.21	79.42	80.01	83.11	83.11	+4.04	95.00
EUR/JPY (average)	102.91	100.64	102.18	107.15	107.15	-1.81	125.00
INR/JPY (average)	1.59	1.54	1.50	1.50	1.50	-0.23	1.75

Appreciation of JPY to USD, EUR, and INR negatively affected the FY2012 Q4 results by 20 bil yen in net sales and 3 bil yen in operating income.  
Annual impact of one yen change is estimated to affect the group's FY2013 performance by; USD: net sales 2.0 bil yen, operating income minor / EUR: net sales 0.6 bil yen, operating income minor

### 3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%		211.9	+17.3%		812.4	49.2	+6.5%
Inter-segment sales		0.3			0.3			0.7			0.5			1.8	1.3	
<b>Net sales</b>	<b>100%</b>	<b>183.8</b>	<b>-4.2%</b>	<b>100%</b>	<b>194.2</b>	<b>+4.4%</b>	<b>100%</b>	<b>223.8</b>	<b>+9.2%</b>	<b>100%</b>	<b>212.4</b>	<b>+17.6%</b>	<b>100%</b>	<b>814.2</b>	<b>50.6</b>	<b>+6.6%</b>
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%	29%	61.2	+35.5%	29%	232.5	45.3	+24.2%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%	71%	151.1	+11.6%	71%	581.7	5.2	+0.9%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%	67%	142.3	+1.5%	61%	497.8	4.9	+1.0%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%	23%	49.3	-9.2%	22%	175.5	-1.4	-0.8%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%	44%	93.0	+8.2%	40%	322.2	6.3	+2.0%
<b>Operating Income</b>	<b>11%</b>	<b>20.1</b>	<b>-49.3%</b>	<b>10%</b>	<b>20.3</b>	<b>+8.9%</b>	<b>16%</b>	<b>34.7</b>	<b>+15.1%</b>	<b>4%</b>	<b>8.9</b>	<b>-</b>	<b>10%</b>	<b>84.0</b>	<b>0.3</b>	<b>+0.4%</b>
Non-operating income		2.1			1.0			2.5			1.7			7.3	-0.8	
Non-operating expenses		1.0			1.6			1.2			1.8			5.6	0.8	
<b>Ordinary Income</b>	<b>11%</b>	<b>21.1</b>	<b>-49.2%</b>	<b>10%</b>	<b>19.8</b>	<b>+4.2%</b>	<b>16%</b>	<b>36.1</b>	<b>+16.1%</b>	<b>4%</b>	<b>8.8</b>	<b>-</b>	<b>11%</b>	<b>85.7</b>	<b>-1.3</b>	<b>-1.4%</b>
Extraordinary income		2.0			0.4			0.6			8.9			11.9	-2.4	
Extraordinary losses		1.3			5.7			6.3			2.5			15.8	0.1	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%	7%	15.2	-	10%	81.8	-3.8	-4.4%
Income taxes		8.1			4.4			6.9			-4.7			14.7	-36.6	
Minority interests		-0.1			-0.0			0.2			-0.0					
<b>Net Income</b>	<b>7%</b>	<b>13.7</b>	<b>-40.1%</b>	<b>5%</b>	<b>10.2</b>	<b>-4.6%</b>	<b>10%</b>	<b>23.2</b>	<b>+110.3%</b>	<b>9%</b>	<b>19.9</b>	<b>-</b>	<b>8%</b>	<b>67.0</b>	<b>29.7</b>	<b>+79.4%</b>

Ranbaxy Group																
	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%		40.3	-34.6%		185.4	9.9	+5.7%
Inter-segment sales		0.7			0.3			0.3			0.4			1.7	0.6	
<b>Net sales</b>	<b>100%</b>	<b>59.8</b>	<b>+49.5%</b>	<b>100%</b>	<b>47.9</b>	<b>+24.1%</b>	<b>100%</b>	<b>38.6</b>	<b>+7.5%</b>	<b>100%</b>	<b>40.8</b>	<b>-34.3%</b>	<b>100%</b>	<b>187.1</b>	<b>10.5</b>	<b>+6.0%</b>
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%	56%	22.9	+0.6%	45%	83.9	2.2	+2.7%
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%	44%	17.9	-54.5%	55%	103.2	8.4	+8.8%
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%	45%	18.4	-31.2%	44%	81.4	6.9	+9.3%
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%	5%	2.1	-11.6%	4%	8.1	-1.2	-12.9%
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%	40%	16.3	-33.0%	39%	73.3	8.1	+12.5%
<b>Operating Income</b>	<b>23%</b>	<b>13.8</b>	<b>+161.9%</b>	<b>12%</b>	<b>5.6</b>	<b>+238.2%</b>	<b>7%</b>	<b>2.9</b>	<b>+238.4%</b>	<b>-1%</b>	<b>-0.5</b>	<b>-103.9%</b>	<b>12%</b>	<b>21.8</b>	<b>1.4</b>	<b>+7.0%</b>
Non-operating income		8.3			-6.2			5.7			2.8			10.4	7.3	
Non-operating expenses		0.8			8.6			-2.5			6.2			13.2	-13.9	
<b>Ordinary Income</b>	<b>36%</b>	<b>21.2</b>	<b>+269.3%</b>	<b>-19%</b>	<b>-9.2</b>	<b>-317.5%</b>	<b>29%</b>	<b>11.0</b>	<b>-</b>	<b>-10%</b>	<b>-3.9</b>	<b>-</b>	<b>10%</b>	<b>19.1</b>	<b>22.6</b>	<b>-</b>
Extraordinary income		0.0			0.0			0.0			0.0			0.1	-0.9	
Extraordinary losses		0.1			-0.0			0.0			3.2			3.4	-38.0	
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-	-17%	-7.1	-	9%	15.9	59.6	-
Income taxes		6.1			-2.3			3.6			-1.1			6.3	16.5	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.0	
<b>Net Income</b>	<b>25%</b>	<b>15.0</b>	<b>+118.9%</b>	<b>-14%</b>	<b>-6.9</b>	<b>-297.1%</b>	<b>19%</b>	<b>7.4</b>	<b>-</b>	<b>-15%</b>	<b>-6.1</b>	<b>-</b>	<b>5%</b>	<b>9.4</b>	<b>43.1</b>	<b>-</b>

Inter-segment Transactions																
	Q1	Q2	Q3	Q4	FY2012											
	Results	Results	Results	Results	Results	YoY	YoY	YoY	YoY							
<b>Net sales</b>	<b>-1.0</b>	<b>-0.6</b>	<b>-1.0</b>	<b>-0.9</b>	<b>-3.5</b>											
Cost of sales	-0.7	-0.4	-0.9	-0.7	-2.7											
Gross Profit	-0.3	-0.2	-0.0	-0.2	-0.7											
SG&A expenses	1.1	1.2	1.1	1.2	4.6											
R&D expenses	-0.3	-0.1	-0.1	-0.1	-0.6											
Other expenses	1.4	1.3	1.3	1.3	5.2											
<b>Operating Income</b>	<b>-1.4</b>	<b>-1.4</b>	<b>-1.1</b>	<b>-1.4</b>	<b>-5.3</b>											
Non-operating income	-0.0	-0.1	-0.1	0.0	-0.2											
Non-operating expenses	0.1	0.0	0.0	0.0	0.2											
<b>Ordinary Income</b>	<b>-1.5</b>	<b>-1.5</b>	<b>-1.2</b>	<b>-1.4</b>	<b>-5.7</b>											
Extraordinary income	-	0.0	0.0	0.1	0.1											
Extraordinary losses	0.0	-0.0	0.0	0.0	0.0											
Income before income taxes and minority interests	-1.5	-1.5	-1.2	-1.4	-5.6											
Income taxes	2.6	0.9	-0.3	-0.3	3.0											
Minority interests	4.2	-3.1	2.6	-2.4	1.3											
<b>Net Income</b>	<b>-8.3</b>	<b>0.7</b>	<b>-3.5</b>	<b>1.3</b>	<b>-9.8</b>											

#### 4. Sales by Business Units

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			FY2013	
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
JPY Bn																		
<b>Consolidated Net Sales</b>	<b>990.0</b>	<b>242.6</b>	<b>+4.7%</b>	<b>25%</b>	<b>241.6</b>	<b>+7.7%</b>	<b>24%</b>	<b>261.5</b>	<b>+8.8%</b>	<b>26%</b>	<b>252.2</b>	<b>+4.1%</b>	<b>26%</b>	<b>997.9</b>	<b>+6.3%</b>	<b>101%</b>	<b>1,080.0</b>	<b>+8.2%</b>
<b>Japan Company (domestic sales)</b>	<b>440.0</b>	<b>98.2</b>	<b>-2.2%</b>	<b>22%</b>	<b>106.9</b>	<b>+6.3%</b>	<b>24%</b>	<b>124.7</b>	<b>+9.5%</b>	<b>28%</b>	<b>112.7</b>	<b>+18.8%</b>	<b>26%</b>	<b>442.5</b>	<b>+8.0%</b>	<b>101%</b>	<b>480.0</b>	<b>+8.5%</b>
Olmotec	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%	81.0	+3.4%
Rezaltas	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%	24.0	+41.9%
Calblock	10.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%	2.6	-5.5%	26%	10.9	-11.8%	109%	9.0	-17.6%
Loxonin	60.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%	13.7	+0.0%	23%	59.6	-2.3%	99%	61.0	+2.3%
Cravit	35.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%	8.8	+1.6%	25%	35.9	-1.2%	103%	36.0	+0.3%
Nexium	22.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%	8.9	+1113.9%	40%	21.6	+452.0%	98%	38.0	+76.3%
Memyary	26.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%	6.4	+103.0%	25%	23.8	+142.0%	92%	36.0	+51.2%
Mevalotin	26.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%	6.0	-12.4%	23%	25.8	-21.9%	99%	23.0	-11.0%
Artist	22.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%	5.3	-5.6%	24%	22.4	-8.8%	102%	22.0	-1.6%
Omnipaque	20.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%	4.6	-11.1%	23%	20.2	-14.3%	101%	19.0	-5.8%
Urief	11.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%	2.7	+5.7%	25%	11.1	+1.0%	101%	12.0	+8.1%
Inavir	11.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%	8.6	-2.0%	78%	11.1	+3.8%	101%	10.0	-10.2%
Ranmark	5.0	0.6	-	12%	1.1	-	22%	1.3	-	27%	1.4	-	27%	4.4	-	88%	6.0	+35.8%
Vaccines	not disclosed	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-	4.7	+3.5%	-	29.8	+40.2%	-	not disclosed	-
Daiichi Sankyo Espha products	not disclosed	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-	2.6	+20.7%	-	11.1	+12.2%	-	not disclosed	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>48.0</b>	<b>10.2</b>	<b>+5.0%</b>	<b>21%</b>	<b>12.8</b>	<b>+1.1%</b>	<b>27%</b>	<b>14.5</b>	<b>+6.1%</b>	<b>30%</b>	<b>9.5</b>	<b>-2.4%</b>	<b>20%</b>	<b>47.1</b>	<b>+2.7%</b>	<b>98%</b>	<b>48.0</b>	<b>+1.9%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>139.0</b>	<b>35.9</b>	<b>+3.7%</b>	<b>26%</b>	<b>32.6</b>	<b>+10.0%</b>	<b>24%</b>	<b>37.4</b>	<b>+23.9%</b>	<b>27%</b>	<b>36.4</b>	<b>+11.6%</b>	<b>26%</b>	<b>142.3</b>	<b>+12.0%</b>	<b>102%</b>	<b>150.0</b>	<b>+5.4%</b>
Olmesartan	93.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%	23.6	+7.0%	25%	94.9	+7.9%	102%	86.0	-9.4%
Benicar/Benicar HCT	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%	67.0	-8.5%
Azor	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%	12.0	-19.1%
Tribenzor	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%	6.0	-12.0%
Welchol	31.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%	9.3	+39.4%	30%	33.1	+23.4%	107%	46.0	+38.8%
Effient (alliance revenue)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-	not disclosed	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>38.0</b>	<b>11.3</b>	<b>-10.9%</b>	<b>30%</b>	<b>7.7</b>	<b>-17.4%</b>	<b>20%</b>	<b>11.3</b>	<b>-24.7%</b>	<b>30%</b>	<b>8.2</b>	<b>+7.7%</b>	<b>22%</b>	<b>38.6</b>	<b>-13.7%</b>	<b>102%</b>	<b>40.0</b>	<b>+3.6%</b>
Venofer	23.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%	4.7	+60.9%	20%	23.6	-4.9%	103%	19.0	-19.6%
<b>Daiichi Sankyo Europe GmbH</b>	<b>65.0</b>	<b>13.9</b>	<b>-17.6%</b>	<b>21%</b>	<b>15.1</b>	<b>-10.8%</b>	<b>23%</b>	<b>16.9</b>	<b>-2.6%</b>	<b>26%</b>	<b>18.5</b>	<b>-3.0%</b>	<b>29%</b>	<b>64.4</b>	<b>-8.3%</b>	<b>99%</b>	<b>73.0</b>	<b>+13.4%</b>
Olmesartan	48.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%	13.9	-3.1%	29%	48.0	-5.9%	100%	56.0	+16.6%
Olmotec/Olmotec Plus	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%	37.0	+13.6%
Sevikar	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%	11.0	+2.2%
Sevikar HCT	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%	7.0	+49.8%
Efient (alliance revenue)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-	not disclosed	-

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			FY2013	
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
<b>Asia, South and Central America (ASCA)<sup>*1</sup></b>	<b>38.0</b>	<b>7.1</b>	<b>+9.8%</b>	<b>19%</b>	<b>8.1</b>	<b>+10.1%</b>	<b>21%</b>	<b>8.2</b>	<b>+18.4%</b>	<b>22%</b>	<b>17.1</b>	<b>+117.8%</b>	<b>45%</b>	<b>40.5</b>	<b>+41.6%</b>	<b>107%</b>	<b>46.0</b>	<b>+13.7%</b>
Daiichi Sankyo China <sup>*2</sup>	not disclosed	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-	7.6	+214.7%	-	16.4	+68.8%	-	not disclosed	-
Daiichi Sankyo Taiwan	not disclosed	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-	0.9	+19.5%	-	3.3	+4.7%	-	not disclosed	-
Daiichi Sankyo Korea	not disclosed	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-	1.6	+40.0%	-	5.3	+15.8%	-	not disclosed	-
Daiichi Sankyo (Thailand)	not disclosed	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-	0.4	+38.7%	-	1.4	+15.6%	-	not disclosed	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-	3.2	+118.5%	-	6.6	+18.6%	-	not disclosed	-
Daiichi Sankyo Venezuela	not disclosed	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-	2.9	+75.9%	-	6.7	+60.7%	-	not disclosed	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.1	-	-	0.1	-	-	0.1	-	-	0.4	-	-	0.7	-	-	not disclosed	-
<b>Ranbaxy Laboratories Limited</b>	<b>179.0</b>	<b>59.1</b>	<b>+48.7%</b>	<b>33%</b>	<b>47.6</b>	<b>+24.0%</b>	<b>27%</b>	<b>38.3</b>	<b>+7.5%</b>	<b>21%</b>	<b>40.3</b>	<b>-34.6%</b>	<b>23%</b>	<b>185.4</b>	<b>+5.7%</b>	<b>104%</b>	<b>217.0</b>	<b>+17.0%</b>
<b>Others</b>	<b>43.0</b>	<b>6.8</b>	<b>-38.0%</b>	<b>16%</b>	<b>10.7</b>	<b>+13.1%</b>	<b>25%</b>	<b>10.0</b>	<b>+32.8%</b>	<b>23%</b>	<b>9.5</b>	<b>+7.5%</b>	<b>22%</b>	<b>37.1</b>	<b>+0.5%</b>	<b>86%</b>	<b>26.0</b>	<b>-29.9%</b>
Levofloxacin export, royalty, etc	3.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%	0.6	-59.6%	21%	4.3	-47.8%	142%	-	-
Plexxikon	not disclosed	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-	0.5	-35.9%	-	3.1	-47.7%	-	not disclosed	-

Currency rates for overseas subsidiaries		Q1 Results	Q2 YTD Results	Q3 YTD Results	Q4 YTD Results	FY2012 Results	FY2013 Forecast
USD/JPY (average)	80.00	80.21	79.42	80.01	83.11	83.11	95.00
EUR/JPY (average)	100.00	102.91	100.64	102.18	107.15	107.15	125.00
INR/JPY (average)	-	1.59	1.54	1.50	1.50	1.50	1.75

**New Product Launches**  
Apr 2012: Ranmark (anti-RANKL antibody for the treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors) launched in Japan.  
Sep 2012: Tenelia ( DPP-4 inhibitor for the treatment of type 2 diabetes mellitus ) launched in Japan.□

**Notes**  
<sup>\*1</sup> Since companies in China, Brazil, Venezuela and Mexico will change their fiscal year-ends from December to March, their FY2012 financial results will be for 15 months.  
<sup>\*2</sup> Daiichi Sankyo Pharmaceutical (Beijing) and Daiichi Sankyo Pharmaceutical (Shanghai) are consolidated as Daiichi Sankyo China.



**[Reference] Sales in Local Currency**

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			FY2013	
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
USD Mn																		
<b>Daiichi Sankyo, Inc. (US)</b>	<b>1,711</b>	<b>448</b>	<b>+5.7%</b>	<b>26%</b>	<b>415</b>	<b>+8.7%</b>	<b>24%</b>	<b>461.0</b>	<b>+18.2%</b>	<b>27%</b>	<b>389.0</b>	<b>-5.6%</b>	<b>23%</b>	<b>1,713</b>	<b>+6.5%</b>	<b>100%</b>	<b>1,579</b>	<b>-7.8%</b>
Olmesartan	1,144	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%	251	-9.9%	22%	1,142	+2.7%	100%	905	-20.7%
Benicar/Benicar HCT	898	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%	184	-19.6%	20%	881	-2.2%	98%	705	-20.0%
Azor	172	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%	44	+22.2%	25%	179	+17.3%	104%	126	-29.2%
Tribenzor	75	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%	23	+66.5%	31%	82	+40.6%	109%	63	-23.0%
Welchol	388	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%	101	+19.8%	26%	399	+17.4%	103%	484	+21.4%
Effient (alliance revenue)	not disclosed	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-	33	-5.7%	-	127	+26.2%	-	not disclosed	-
USD Mn																		
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>468</b>	<b>141</b>	<b>-9.2%</b>	<b>30%</b>	<b>98</b>	<b>-18.5%</b>	<b>21%</b>	<b>140.0</b>	<b>-27.6%</b>	<b>30%</b>	<b>85.0</b>	<b>-11.8%</b>	<b>18%</b>	<b>465</b>	<b>-17.9%</b>	<b>99%</b>	<b>421</b>	<b>-9.4%</b>
Venofer	288	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%	47	+29.8%	16%	284	-9.6%	99%	200	-29.6%
EUR Mn																		
<b>Daiichi Sankyo Europe GmbH</b>	<b>650</b>	<b>135</b>	<b>-6.0%</b>	<b>21%</b>	<b>153</b>	<b>-0.2%</b>	<b>24%</b>	<b>161.0</b>	<b>-2.6%</b>	<b>25%</b>	<b>152.0</b>	<b>-16.6%</b>	<b>23%</b>	<b>601</b>	<b>-6.7%</b>	<b>93%</b>	<b>584</b>	<b>-2.8%</b>
Olmesartan	480	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%	114	-16.5%	24%	448	-4.3%	93%	448	+0.0%
Olmetec/Olmetec Plus	340	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%	78	-17.8%	23%	304	-9.6%	89%	296	-2.6%
Sevikar	100	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%	23	-26.4%	23%	100	-0.3%	100%	88	-12.4%
Sevikar HCT	40	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%	13	+27.1%	32%	44	+40.5%	109%	56	+28.4%
Effient (alliance revenue)	not disclosed	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-	10	-1.0%	-	36	+34.1%	-	not disclosed	-
INR Bn																		
<b>Ranbaxy Laboratories Limited</b>	<b>105</b>	<b>37</b>	<b>+71.1%</b>	<b>35%</b>	<b>32</b>	<b>+53.1%</b>	<b>31%</b>	<b>27.0</b>	<b>+31.2%</b>	<b>26%</b>	<b>27.0</b>	<b>-28.9%</b>	<b>26%</b>	<b>124</b>	<b>+21.9%</b>	<b>117%</b>	<b>120 or over</b>	<b>-</b>



## 5. Sales of Global Products

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			FY2013	
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
JPY Bn																		
<b>Olmesartan</b>	<b>251.0</b>	<b>60.0</b>	<b>-5.3%</b>	<b>24%</b>	<b>60.8</b>	<b>+0.6%</b>	<b>24%</b>	<b>68.3</b>	<b>+6.4%</b>	<b>27%</b>	<b>69.7</b>	<b>+13.0%</b>	<b>28%</b>	<b>258.9</b>	<b>+3.7%</b>	<b>103%</b>	<b>269.0</b>	<b>+3.9%</b>
Olmetec (JPN)	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%	81.0	+3.4%
Rezaltas (JPN)	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%	24.0	+41.9%
Benicar/Benicar HCT (US)	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%	67.0	-8.5%
Azor (US)	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%	12.0	-19.1%
Tribenzor (US)	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%	6.0	-12.0%
Olmetec/Olmetec Plus (EU)	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%	37.0	+13.6%
Sevikar (EU)	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%	11.0	+2.2%
Sevikar HCT (EU)	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%	7.0	+49.8%
Other subsidiaries, export, etc	18.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.3	-3.1%	24%	8.1	+82.8%	45%	20.7	+25.7%	115%	24.0	+15.8%
<b>Prasugrel</b>	<b>not disclosed</b>	<b>3.3</b>	<b>+52.6%</b>	<b>-</b>	<b>3.2</b>	<b>+37.5%</b>	<b>-</b>	<b>3.7</b>	<b>+43.5%</b>	<b>-</b>	<b>4.2</b>	<b>+10.4%</b>	<b>-</b>	<b>14.4</b>	<b>+32.5%</b>	<b>-</b>	<b>not disclosed</b>	<b>-</b>
Effient alliance revenue (US)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-	not disclosed	-
Effient alliance revenue (EU)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-	not disclosed	-

## 6. Number of Employees

	Mar 2012 Results	Jun 2012 Results	Sep 2012 Results	Dec 2012 Results	Mar 2013 Results
<b>Total Number of Employees</b>	<b>31,929</b>	<b>32,522</b>	<b>32,563</b>	<b>32,456</b>	<b>32,229</b>
Japan	9,308	9,435	9,338	9,318	9,251
* Overseas	22,621	23,087	23,225	23,138	22,978
Daiichi Sankyo Group	17,877	18,043	18,042	17,780	17,528
* Ranbaxy Group	14,052	14,479	14,521	14,676	14,701

\* For overseas subsidiaries with different fiscal year-ends, numbers as of Dec-end are shown in the Mar-end columns

## 7. Management / Financial Indicators

	FY2010 Results	FY2011 Results	FY2012 Q2 YTD Results	FY2012 Results	FY2013 Forecast
<b>Management Indicators</b>					
Earnings per share (EPS)	99.6 Yen	14.8 Yen	34.6 Yen	94.6 Yen	96.6 Yen
Dividend per share	60.0 Yen	60.0 Yen	30.0 Yen	60.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	60.2 %	406.8 %	86.7 %	63.4 %	62.1 %
Dividend payment	42 JPY Bn	42 JPY Bn	21 JPY Bn	42 JPY Bn	
Return on equity (ROE)	8.2 %	1.3 %	- %	7.9 %	
Dividend on equity (DOE)	5.0 %	5.1 %	- %	5.0 %	
Book value per share (BPS)	1,206.1 Yen	1,143.5 Yen	1,126.4 Yen	1,253.9 Yen	
Equity ratio	57.4 %	53.0 %	53.0 %	53.7 %	
Total number of common shares	704 million	704 million	704 million	704 million	
Share price at end of period	1,606 Yen	1,508 Yen	1,290 Yen	1,815 Yen	
Market value	1,130.4 JPY Bn	1,069.2 JPY Bn	908.1 JPY Bn	1,277.7 JPY Bn	
<b>Financial Indicators</b>					
Total assets	1,480.2 JPY Bn	1,518.5 JPY Bn	1,495.0 JPY Bn	1,644.1 JPY Bn	
Current assets	894.1 JPY Bn	861.5 JPY Bn	845.1 JPY Bn	943.6 JPY Bn	
*1 Liquidity on hand	426.8 JPY Bn	324.3 JPY Bn	314.4 JPY Bn	374.7 JPY Bn	
Debt with interest	299.4 JPY Bn	275.9 JPY Bn	270.5 JPY Bn	267.7 JPY Bn	
Net Cash	127.4 JPY Bn	48.4 JPY Bn	43.9 JPY Bn	107.0 JPY Bn	
Equity capital	849.0 JPY Bn	804.9 JPY Bn	792.9 JPY Bn	882.6 JPY Bn	
Cash flow from operating activities	141.1 JPY Bn	92.6 JPY Bn	56.5 JPY Bn	129.2 JPY Bn	
Cash flow from investing activities	-63.0 JPY Bn	-125.1 JPY Bn	-102.0 JPY Bn	-109.3 JPY Bn	
Cash flow from financial activities	-26.0 JPY Bn	-50.2 JPY Bn	-26.0 JPY Bn	-57.3 JPY Bn	
*2 Free cash flow	78.2 JPY Bn	-32.5 JPY Bn	-45.6 JPY Bn	20.0 JPY Bn	
Cash and cash equivalents, end of period	302.4 JPY Bn	212.7 JPY Bn	137.7 JPY Bn	190.9 JPY Bn	
<b>Others</b>					
Number of consolidated subsidiaries	101	103	105	104	

\*1 Current deposits + marketable securities + investment securities, etc

\*2 Cash flow from operating activities and investing activities

## 8. Capital Expenditure and Depreciation and Amortization Expenses

	FY2010 Results	FY2011 Results	FY2012 Q2 YTD Results	FY2012 Results	FY2013 Plan
Capital expenditure	37.3 JPY Bn	62.9 JPY Bn	31.5 JPY Bn	65.1 JPY Bn	80.0 JPY Bn
Depreciation and amortization expense	43.9 JPY Bn	46.3 JPY Bn	20.2 JPY Bn	41.4 JPY Bn	42.0 JPY Bn
Tangible assets	27.5 JPY Bn	29.4 JPY Bn	12.3 JPY Bn	25.6 JPY Bn	
Intangible assets	16.5 JPY Bn	16.8 JPY Bn	7.9 JPY Bn	15.8 JPY Bn	

## 9. Consolidated Balance Sheets

(Billions of yen)

	Mar 2012	Mar 2013	YoY	Notes
<b>ASSETS</b>				
Current assets				
Cash and time deposits	128.9	161.0	32.0	PBT +92.1 Bn, Depreciation, amortization and impairment loss +62.0 Bn Net purchase and acquisitions of proceeds from sales of non-current assets -72.2 Bn Dividend paid -42.2 Bn, Income taxes paid -23.6 Bn Net decrease in loans payable and bonds payable -15.1 Bn
Trade notes and accounts receivable	228.5	238.5	10.0	
Marketable securities	191.3	211.3	20.0	
Merchandise and finished goods	109.3	113.2	3.9	
Work in process	24.5	21.8	-2.7	
Raw materials and supplies	35.8	39.4	3.6	
Deferred tax assets	94.0	111.1	17.1	
Other current assets	51.3	50.0	-1.3	
Allowance for doubtful accounts	-2.2	-2.7	-0.5	
Total current assets	861.5	943.6	82.1	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	129.3	138.3	8.9	
Machinery, equipment and vehicles, net	48.1	63.5	15.4	
Land	35.7	35.8	0.1	
Construction in progress	33.7	47.9	14.2	
Other, net	14.5	18.0	3.5	
Total property, plant and equipment	261.2	303.4	42.2	Newly added: Kitasato Daiichi Sankyo Vaccine (KDSV) +25.6 Bn, Daiichi Sankyo +14.9 Bn
Intangible assets				
Goodwill, net	82.7	73.5	-9.2	
Other intangible assets, net	150.5	149.9	-0.6	
Total intangible assets	233.3	223.5	-9.8	
Investments and other assets				
Investment securities	104.6	129.2	24.6	
Deferred tax assets	43.2	32.5	-10.6	
Other	15.0	12.1	-2.8	
Allowance for doubtful accounts	-0.3	-0.3	0.0	
Total investments and other assets	162.4	173.5	11.1	
Total non-current assets	656.9	700.4	43.5	
<b>Total assets</b>	<b>1,518.5</b>	<b>1,644.1</b>	<b>125.6</b>	

(Billions of yen)

	Mar 2012	Mar 2013	YoY	Notes
<b>LIABILITIES</b>				
Current liabilities				
Trade notes and accounts payable	61.8	59.8	-2.0	
Short-term loans payable	71.1	66.1	-5.0	
Income taxes payable	5.3	23.2	17.9	
Allowance for sales returns	0.6	0.6	0.0	
Allowance for sales rebates	2.9	2.0	-0.9	
Provision for loss on disaster	0.8	0.0	-0.8	
Provision for settlement expenses	39.1	43.7	4.6	
Provision for environment measures	0.0	1.3	1.3	
Accrued expenses	74.7	89.0	14.3	
Other current liabilities	138.7	150.4	11.7	
<b>Total current liabilities</b>	<b>395.0</b>	<b>436.1</b>	<b>41.1</b>	
Long-term liabilities				
Bonds payable	100.0	107.9	7.9	
Long-term loans payable	104.0	93.0	-11.0	
Deferred tax liabilities	52.1	45.1	-7.0	
Accrued employees' severance and retirement benefits	10.1	13.9	3.8	
Accrued directors' severance and retirement benefits	0.2	0.2	0.0	
Provision for environment measures	1.2	0.0	-1.2	
Other long-term liabilities	23.2	32.1	8.9	
<b>Total long-term liabilities</b>	<b>290.8</b>	<b>292.2</b>	<b>1.5</b>	
<b>Total liabilities</b>	<b>685.7</b>	<b>728.3</b>	<b>42.6</b>	
<b>NET ASSETS</b>				
Shareholders' equity				
Common stock	50.0	50.0	0.0	
Capital surplus	105.2	105.2	0.0	
Retained earnings	742.4	766.7	24.3	Net income +66.6 Bn, Dividend paid -42.2 Bn
Treasury stock, at cost	-14.6	-14.5	0.1	
<b>Total shareholders' equity</b>	<b>883.0</b>	<b>907.5</b>	<b>24.4</b>	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	22.3	34.2	11.9	
Deferred gains or losses on hedges	0.2	0.9	0.7	
Foreign currency translation adjustments	-100.6	-60.0	40.6	Increase in net assets of overseas subsidiaries on a JPY basis +40.6 Bn
<b>Total accumulated other comprehensive income</b>	<b>-78.1</b>	<b>-24.8</b>	<b>53.3</b>	
Subscription rights to shares	3.5	4.1	0.6	
Minority interests	24.3	29.0	4.7	Ranbaxy +4.6 Bn
<b>Total net assets</b>	<b>832.7</b>	<b>915.7</b>	<b>83.0</b>	
<b>Total liabilities and net assets</b>	<b>1,518.5</b>	<b>1,644.1</b>	<b>125.6</b>	

## 10. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2011 Q4 Results	FY2012 Q4 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	33.9	92.1	58.2	
Depreciation and amortization of goodwill	57.4	52.5	-4.8	
Increase/decrease in trade receivable and payable	4.4	-12.9	-17.3	
Other, net	28.8	21.1	-7.7	
Income taxes paid	-31.9	-23.6	8.3	
Net cash provided by operating activities	92.6	129.2	36.7	
Cash flows from investing activities				
Net (increase) decrease in short-term investments	10.0	-65.6	-75.6	
(Acquisition of) proceeds from sales of non-current assets	-50.6	-72.2	-21.6	
Acquisition of investments in subsidiaries	-71.3	-0.0	71.3	FY2011: Plexikon Inc -71.3 Bn
Other, net	-13.2	28.5	41.7	FY2011: Kitasato Daiichi Sankyo Vaccine (KDSV) - Payment for transfer of business -16.1 Bn
Net cash used in investing activities	-125.1	-109.3	15.8	
Cash flows from financing activities				
Net increase (decrease) in loans payable	26.3	-22.6	-48.9	
Proceeds from issuance of bonds	—	7.5	7.5	Ranbaxy
Redemption of bonds	-45.0	—	45.0	FY2011: Redemption of Ranbaxy's foreign currency convertible bond
Dividends paid	-42.8	-42.2	0.6	
Other, net	11.4	-0.0	-11.4	FY2011: Investment in KDSV from The Kitasato Institute
Net cash used in financing activities	-50.2	-57.3	-7.1	
Effect of exchange rate changes on cash and cash equivalents	-7.0	15.6	22.6	
Net increase (decrease) in cash and cash equivalents	-89.7	-21.8	68.0	
Cash and cash equivalents, beginning of period	302.4	212.7	-89.7	
Cash and cash equivalents, at end of period	212.7	190.9	-21.8	

## 11. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
<b>Japan Company (domestic sales)</b>					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe
<b>Daiichi Sankyo, Inc. (US)</b>					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
<b>Luitpold Pharmaceuticals, Inc. (US)</b>					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
<b>Daiichi Sankyo Europe GmbH</b>					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly



**12. Major R&D Pipeline (Innovative pharmaceuticals)**

As of May, 2013

◆ **Approved**

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP Approved	Approved in Mar 2013
<p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors.</p>					

◆ **Filed**

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP Filed	Filed in Nov 2012
<p>The long-acting neuraminidase inhibitor which was developed and produced by Daiichi Sankyo. This is an inhalant that will act directly on the pulmonary and tracheal sites of infection. Launched in Japan in October 2010 as treatment for influenza A and influenza B viruses.</p>					

◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks	
DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	Global	P3	Application to be expected in 2H FY2013
			Venous thromboembolism (VTE)	Global	P3	Application to be expected in 2H FY2013
CS-747	prasugrel	Anti-platelet agent	Acute coronary syndrome (ACS-PCI)	JP	P3	Application to be expected in 1H FY2013
			Coronary artery disease with elective PCI	JP	P3	Application to be expected in 1H FY2013
			Ischemic Stroke	JP	P3	Study to be completed in FY2014
			Sickle cell disease	US	P3	
AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	
			Rheumatoid arthritis	JP	P2	
			Giant cell tumor	JP	P2	
DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3	
ARQ 197	tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	
			Colorectal cancer	US/EU	P2	
DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	
			Non small cell lung cancer	JP	P3	
			Esophageal cancer	JP	P1	
CS-3150	-	MR antagonist	Hypertension	JP	P2	
			Diabetic nephropathy	JP	P2	
DS-7250	-	DGAT1 inhibitor	Diabetes	JP	P2	
			Diabetes, Obesity	US/EU	P1	
CS-1008	tigatuzumab	Anti-DR5 antibody	Hepatocellular cancer	Global	P2	
CS-7017	efatutazone	PPAR-gamma agonist	Non small cell lung cancer	US/EU	P2	
			Colorectal cancer	US/EU	P2	
			Non small cell lung cancer	Asia	P1	
			Colorectal cancer	JP	P1	
U3-1287	patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
			Non small cell lung cancer	JP	P1	
			Breast cancer	US	P2	
			Breast cancer	JP	P1	
PLX4032	vemurafenib	BRAF inhibitor	Throid cancer	US/EU	P2	
PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma	US	P2	
			Acute myeloid leukemia	US	P2	
			Glioblastoma	US	P2	
			Prostate Cancer	US	P2	

◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
DS-5565	-	α2δ ligand	Chronic pain	Global	P2
SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2
ASB17061	-	Chymase inhibitor	Atopic Dermatitis	US	P2
DS-7309	-	Glucokinase activator	Diabetes	-	P1
DS-6930	-	Selective PPAR-gamma modulator	Diabetes	-	P1
DS-8500	-	GPR119 agonist	Diabetes	-	P1
DS-1442	-	CETP inhibitor	Dyslipidemia	-	P1
DS-1040	-	TAF1a inhibitor	Acute ischemic stroke	-	P1
U3-1565	-	Anti-HB-EGF antibody	Solid cancer	US/JP	P1
DS-2248	-	HSP90 inhibitor	Solid cancer	US	P1
DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1
DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza	US/EU	P1
DS-8587	-	Topoisomerase inhibitor	Anti-bacterial	-	P1
CS-4771	-	TLR4 inhibitor	Anti-sepsis	-	P1
PLX5622	-	FMS kinase inhibitor	Rheumatoid arthritis	-	P1
CS-0777	-	S1P receptor modulator	Immunomodulator	-	P1
DS-7113	hydromorphone	opioid mu-receptor regulator	Narcotic analgesic	-	P1

◆ Change of stage from announcement in Jan 2013

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP	Approved
CS-747	prasugrel	Anti-platelet agent	Sickle cell disease	US	P3
ARQ 197	tivantinib	Hepatocellular cancer	Hepatocellular cancer	US/EU	P3
DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3
			Non small cell lung cancer	JP	P3
CS-3150	-	MR antagonist	Diabetic nephropathy	JP	P2
DS-1040	-	TAF1a inhibitor	Acute ischemic stroke	-	P1

◆ Discontinue

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
ARQ 092	-	Akt inhibitor	Solid cancer	US	P1
<p>&lt;Reason for discontinue&gt; Daiichi Sankyo decided to discontinue the development of ARQ 092 after carefully reviewing the DS product development portfolio. Daiichi Sankyo will concentrate the resource to other projects in development.</p>					

◆ Major R&D Pipeline Table

As of May, 2013

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<p><b>DS-7309</b> (Anti-diabetes / Glucokinase activator)</p> <p><b>DS-6930</b> (Anti-diabetes / Selective PPAR-gamma modulator)</p> <p><b>DS-8500</b> (Anti-diabetes / GPR119 agonist)</p> <p><b>DS-1442</b> (Dyslipidemia / CETP inhibitor)</p> <p><b>DS-1040</b> (Acute ischemic stroke / TAF1a inhibitor)</p>	<p><b>CS-3150 (JP)</b> (Anti-hypertension / Diabetic nephropathy/ MR antagonist)</p> <p><b>DS-7250 (JP)</b> (Anti-diabetes / DGAT1 inhibitor)</p> <p>○ →</p>	<p><b>DU-176b (Global)</b> (edoxaban / AF / oral factor Xa inhibitor)</p> <p><b>DU-176b (Global)</b> (edoxaban / VTE / oral factor Xa inhibitor)</p> <p><b>CS-747 (JP)</b> (prasugrel / PCI / anti-platelet agent)</p> <p><b>CS-747 (JP)</b> (prasugrel / ischemic stroke / anti-platelet agent)</p> <p><b>CS-747 (US)</b> (prasugrel / Sickle cell disease / anti-platelet agent)</p>	
Oncology	<p><b>U3-1565 (US/JP)</b> (Anti-HB-EGF antibody)</p> <p><b>DS-2248 (US)</b> (HSP90 inhibitor)</p> <p><b>DS-7423 (US/JP)</b> (PI3K/mTOR inhibitor)</p> <p><del><b>ARQ 002 (US)</b> (Akt inhibitor)</del></p> <p><b>DS-3078 (US/EU)</b> (mTOR inhibitor)</p>	<p>○ →</p> <p><b>CS-1008 (Global)</b> (tigatuzumab / anti-DR5 antibody)</p> <p>○ →</p> <p><b>CS-7017 (US/EU)</b> (efatutazone / PPARγ agonist)</p> <p><b>U3-1287 (US/EU)</b> (patritumab / anti-HER3 antibody)</p> <p><b>PLX4032 (US/EU)</b> (vemurafenib / BRAF inhibitor)</p> <p><b>PLX3397 (US)</b> (Fms/Kit/Flt3-ITD inhibitor)</p>	<p><b>ARQ 197 (US/EU)</b> (tivantinib / HCC / MET inhibitor)</p> <p><b>AMG 162 (JP)</b> (denosumab / breast cancer adjuvant / anti-RANKL antibody)</p> <p><b>DE-766 (JP)</b> (nimotuzumab / NSCLC / anti-EGFR antibody)</p> <p><b>DE-766 (JP)</b> (nimotuzumab / Gastric cancer / anti-EGFR antibody)</p>	
Others	<p><b>CS-8958 (US/EU)</b> (laninamivir / anti-influenza / Outlicensing with Biota)</p> <p><b>DS-8587</b> (Anti-bacterial / Topoisomerase inhibitor )</p> <p><b>CS-4771</b> (Anti-sepsis / TLR4 inhibitor)</p> <p><b>PLX5622</b> (Rheumatoid arthritis / FMS kinase inhibitor)</p> <p><b>CS-0777</b> (Immunomodulator / S1P receptor modulator)</p> <p><b>DS-7113</b> (hydromorphone / Narcotic analgesic / opioid mu-receptor regulator )</p>	<p><b>AMG 162 (JP)</b> (denosumab / Rheumatoid arthritis / anti-RANKL antibody)</p> <p><b>DS-5565 (Global)</b> (Chronic pain / α2δ ligand)</p> <p><b>SUN13837 (US/EU)</b> (Spinal cord injury / Modulator of bFGF signaling system)</p> <p><b>ASB17061 (US)</b> (Atopic Dermatitis / chymase inhibitor)</p>	<p><b>DR-3355 (JP)</b> (levofloxacin / anti-infection / New quinolone)</p>	<p><b>CS-8958 (JP)</b> (laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p> <p><b>AMG 162 (JP)</b> → (denosumab / osteoporosis / anti-RANKL antibody)</p>

# Cardiovascular-Metabolics

[ Project after Phase 2 ]

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DU-176b	edoxaban	Oral	Factor Xa inhibitor	Atrial fibrillation (AF) Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana(JP)
<ul style="list-style-type: none"> <li>• An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates.</li> <li>• An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials.</li> <li>• No severe hepatotoxicity signals in pre-clinical and clinical trials</li> <li>• [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana</li> <li>• Development by Daiichi Sankyo globally. Both ENGAGE AF-TIMI 48(AF) and HOKUSAI-VTE(VTE) P3 studies will be presented at the major medical congress in FY2013.</li> <li>• NDA for AF/VTE indication to be expected in FY2013.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-747	prasugrel	Oral	Anti-platelet agent	Acute coronary syndrome (ACS-PCI) Elective PCI Ischemic stroke Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efiect (EU)
<ul style="list-style-type: none"> <li>• Inhibition of platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface.</li> <li>• Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan.</li> <li>• A P3 study in pediatric sickle cell disease patients is on-going in US.</li> <li>• [EU] Approved in Feb-2009 for ACS-PCI. Brand name: Efiect</li> <li>• [US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient</li> <li>• [JP] Both PRASFIT-ACS (ACS-PCI) and PRASFIT-Elective (Elective PCI) P3 studies have been completed. P3 studies for ischemic stroke are on-going.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-3150	-	Oral	MR antagonist	Hypertension Diabetic nephropathy	Exelixis	TBD
<ul style="list-style-type: none"> <li>• Inhibitor of MR (mineralocorticoid receptor) binding to aldosterone to show antihypertensive and organ-protective effect</li> <li>• The P2 study in essential hypertension and P2 study in diabetes with albuminuria are ongoing in Japan.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-7250	-	Oral	DGAT1 inhibitor	Diabetes Obesity	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> <li>• Delay TG absorption by inhibition of DGAT1 (Acyl-CoA:Diacylglycerol acyltransferase 1) at enterocyte</li> <li>• P2 study with T2DM patients is ongoing.</li> </ul>						

## Oncology

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ARQ 197	tivantinib	Oral	Met inhibitor	Hepatocellular cancer Colorectal cancer	ArQule	TBD
<ul style="list-style-type: none"> <li>• Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction.</li> <li>• Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc.</li> <li>• A P3 clinical study for HCC was started in Jan-2013.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	Hepatocellular cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> <li>• A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5).</li> <li>• DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells.</li> <li>• Induces apoptosis of tumor cells expressing DR5 on the cell surface.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	Gastric cancer Non small cell lung cancer Esophageal cancer	CIMYM Biosciences	TBD
<ul style="list-style-type: none"> <li>• A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR).</li> <li>• Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies.</li> <li>• P3 in Japan for NSCLC started in March 2013, that for Gastric cancer started in April</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-7017	efatutazone	Oral	PPAR-gamma agonist	Non small cell lung cancer Colorectal cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> <li>• Inhibits growth of tumor cells in vitro without killing those cells.</li> <li>• Expected to be less toxic compared to standard chemotherapeutics.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
U3-1287	patritumab	Injection	Anti-HER3 antibody	Non small cell lung cancer Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<ul style="list-style-type: none"> <li>•HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins.</li> <li>•HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX4032	vemurafenib	Oral	BRAF inhibitor	Thyroid cancer	Daiichi Sankyo (Plexikon)	Zelboraf
<ul style="list-style-type: none"> <li>•Plexikon discovered vemurafenib, and since 2006, has been co-developing it with partner, Roche</li> <li>•Personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma Acute myeloid leukemia Glioblastoma Prostate Cancer	Daiichi Sankyo (Plexikon)	TBD
<ul style="list-style-type: none"> <li>•Plexikon discovered PLX3397.</li> <li>•Clinical studies are on-going for several types of cancer.</li> </ul>						



## Others

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
AMG 162	denosumab	Injection	Anti-RANKL antibody	Osteoporosis Breast cancer adjuvant Rheumatoid arthritis Giant cell tumor	Amgen	SRE: Ranmark(JP) Osteoporosis: Pralia(JP)
<ul style="list-style-type: none"> <li>• Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling.</li> <li>• July, 2007 In-licensed from Amgen</li> <li>• P3 : Breast cancer adjuvant, P2: Rheumatoid arthritis, Giant cell tumor of bone</li> <li>• [JP] NDA approval: Skeletal Related Event(SRE) in Jan-2012, Osteoporosis in Mar-2013</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, Treatment / Prophylactic	Daiichi Sankyo	Inavir(JP)
<ul style="list-style-type: none"> <li>• Long-acting neuraminidase inhibitor</li> <li>• Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan</li> <li>• CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection.</li> <li>• [JP] Application: Prophylactic in Nov-2012</li> <li>• [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DR-3355	levofloxacin	Injection	New quinolone	Anti-infection	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<ul style="list-style-type: none"> <li>• As LCM, additional indications of urinary tract infection, surgical infection and gynecological infection, which are the largest market next to respiratory tract infection are under development.</li> <li>• A P3 comparative study for urinary tract infection and 4 open studies are on-going.</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-5565	-	Oral	$\alpha 2\delta$ ligand	Chronic pain	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> <li>• An <math>\alpha 2\delta</math> ligand that binds to <math>\alpha 2\delta</math> subunit of voltage-dependent <math>Ca^{2+}</math> channels</li> <li>• Considered to decrease excess <math>Ca^{2+}</math> influx to nerve terminals and to lower pain-related neurotransmitter release.</li> <li>• Clinical studies are on-going for diabetic peripheral neuropathic pain</li> </ul>						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
SUN13837	-	Injection	Modulator of bFGF signaling system	Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> <li>• Although SUN13837 acts upon the signal coupled with the FGF receptor and shows similar cell differentiation actions (nerve cell protection, nerve axon elongation) to bFGF, it does not show any cell multiplication function.</li> <li>• By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved</li> <li>• By making perceptual and motor-functional dysfunctions recovered at an early stage of postinjury, remnant functions in the chronic period are to be improved</li> <li>• Clinical studies are on-going for patients with severe spinal cord injury</li> </ul>						

**1. Summary of Consolidated Income Statement (FY2011)**

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>231.7</b>	<b>-9.7%</b>	<b>100%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>100%</b>	<b>240.4</b>	<b>-3.5%</b>	<b>100%</b>	<b>242.3</b>	<b>+10.5%</b>	<b>100%</b>	<b>938.7</b>	<b>-28.7</b>	<b>-3.0%</b>
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
<b>Operating Income</b>	<b>19%</b>	<b>43.5</b>	<b>-28.8%</b>	<b>8%</b>	<b>18.7</b>	<b>-35.6%</b>	<b>12%</b>	<b>29.7</b>	<b>-2.8%</b>	<b>3%</b>	<b>6.3</b>	<b>+318.5%</b>	<b>10%</b>	<b>98.2</b>	<b>-23.9</b>	<b>-19.6%</b>
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
<b>Ordinary Income</b>	<b>19%</b>	<b>44.8</b>	<b>-36.0%</b>	<b>10%</b>	<b>21.5</b>	<b>-4.6%</b>	<b>8%</b>	<b>20.1</b>	<b>-47.1%</b>	<b>-4%</b>	<b>-10.2</b>	<b>-</b>	<b>8%</b>	<b>76.2</b>	<b>-55.5</b>	<b>-42.2%</b>
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
<b>Net Income</b>	<b>11%</b>	<b>25.3</b>	<b>-23.5%</b>	<b>5%</b>	<b>11.7</b>	<b>-38.5%</b>	<b>-8%</b>	<b>-19.5</b>	<b>-</b>	<b>-3%</b>	<b>-7.2</b>	<b>-</b>	<b>1%</b>	<b>10.4</b>	<b>-59.7</b>	<b>-85.2%</b>
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

**2. Currency Rate (FY2011)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

## 3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
<b>Net sales</b>	<b>100%</b>	<b>192.0</b>	<b>-4.8%</b>	<b>100%</b>	<b>186.0</b>	<b>-6.4%</b>	<b>100%</b>	<b>205.0</b>	<b>-4.1%</b>	<b>100%</b>	<b>180.6</b>	<b>-0.4%</b>	<b>100%</b>	<b>763.6</b>	<b>-31.8</b>	<b>-4.0%</b>
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
<b>Operating Income</b>	<b>21%</b>	<b>39.6</b>	<b>-8.5%</b>	<b>10%</b>	<b>18.7</b>	<b>-19.4%</b>	<b>15%</b>	<b>30.2</b>	<b>-2.9%</b>	<b>-3%</b>	<b>-4.8</b>	<b>-</b>	<b>11%</b>	<b>83.7</b>	<b>-16.1</b>	<b>-16.2%</b>
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
<b>Ordinary Income</b>	<b>22%</b>	<b>41.6</b>	<b>-4.2%</b>	<b>10%</b>	<b>19.0</b>	<b>-17.8%</b>	<b>15%</b>	<b>31.1</b>	<b>-7.9%</b>	<b>-3%</b>	<b>-4.6</b>	<b>-</b>	<b>11%</b>	<b>87.0</b>	<b>-13.0</b>	<b>-13.0%</b>
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
<b>Net Income</b>	<b>12%</b>	<b>22.9</b>	<b>+2.5%</b>	<b>6%</b>	<b>10.7</b>	<b>-41.9%</b>	<b>5%</b>	<b>11.0</b>	<b>-57.5%</b>	<b>-4%</b>	<b>-7.2</b>	<b>-</b>	<b>5%</b>	<b>37.4</b>	<b>-21.4</b>	<b>-36.4%</b>
<b>Ranbaxy Group</b>																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
<b>Net sales</b>	<b>100%</b>	<b>40.0</b>	<b>-27.1%</b>	<b>100%</b>	<b>38.6</b>	<b>-11.7%</b>	<b>100%</b>	<b>35.9</b>	<b>+1.1%</b>	<b>100%</b>	<b>62.0</b>	<b>+59.5%</b>	<b>100%</b>	<b>176.6</b>	<b>3.5</b>	<b>+2.0%</b>
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
<b>Operating Income</b>	<b>13%</b>	<b>5.3</b>	<b>-72.7%</b>	<b>4%</b>	<b>1.7</b>	<b>-74.9%</b>	<b>2%</b>	<b>0.9</b>	<b>+34.5%</b>	<b>20%</b>	<b>12.6</b>	<b>+998.6%</b>	<b>12%</b>	<b>20.4</b>	<b>-7.3</b>	<b>-26.4%</b>
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
<b>Ordinary Income</b>	<b>14%</b>	<b>5.8</b>	<b>-79.6%</b>	<b>11%</b>	<b>4.2</b>	<b>+353.5%</b>	<b>-26%</b>	<b>-9.5</b>	<b>-</b>	<b>-6%</b>	<b>-3.9</b>	<b>-</b>	<b>-2%</b>	<b>-3.4</b>	<b>-43.4</b>	<b>-</b>
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
<b>Net Income</b>	<b>17%</b>	<b>6.9</b>	<b>-62.7%</b>	<b>9%</b>	<b>3.5</b>	<b>-22.7%</b>	<b>-16%</b>	<b>-5.6</b>	<b>-</b>	<b>-62%</b>	<b>-38.5</b>	<b>-</b>	<b>-19%</b>	<b>-33.7</b>	<b>-57.1</b>	<b>-</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.3</b>			<b>-0.3</b>			<b>-0.6</b>			<b>-0.4</b>			<b>-1.5</b>		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
<b>Operating Income</b>		<b>-1.4</b>			<b>-1.6</b>			<b>-1.3</b>			<b>-1.5</b>			<b>-5.9</b>		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
<b>Ordinary Income</b>		<b>-2.5</b>			<b>-1.7</b>			<b>-1.5</b>			<b>-1.7</b>			<b>-7.3</b>		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
<b>Net Income</b>		<b>-4.4</b>			<b>-2.4</b>			<b>-24.9</b>			<b>38.5</b>			<b>6.7</b>		

**4. Sales by Business Units (FY2011)**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
<b>Consolidated Net Sales</b>	<b>231.7</b>	<b>-9.7%</b>	<b>24%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>23%</b>	<b>240.4</b>	<b>-3.5%</b>	<b>25%</b>	<b>242.3</b>	<b>+10.5%</b>	<b>25%</b>	<b>938.7</b>	<b>-3.0%</b>	<b>97%</b>
<b>Japan Company (domestic sales)</b>	<b>100.4</b>	<b>-4.6%</b>	<b>23%</b>	<b>100.5</b>	<b>-2.4%</b>	<b>23%</b>	<b>113.9</b>	<b>-2.4%</b>	<b>26%</b>	<b>94.9</b>	<b>+4.3%</b>	<b>22%</b>	<b>409.8</b>	<b>-1.5%</b>	<b>94%</b>
Olmotec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.7</b>	<b>+4.9%</b>	<b>20%</b>	<b>12.7</b>	<b>+8.2%</b>	<b>26%</b>	<b>13.7</b>	<b>+4.1%</b>	<b>28%</b>	<b>9.7</b>	<b>-8.5%</b>	<b>20%</b>	<b>45.9</b>	<b>+2.3%</b>	<b>94%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>34.6</b>	<b>+3.2%</b>	<b>27%</b>	<b>29.7</b>	<b>-12.4%</b>	<b>23%</b>	<b>30.1</b>	<b>-13.0%</b>	<b>23%</b>	<b>32.6</b>	<b>+15.0%</b>	<b>25%</b>	<b>127.1</b>	<b>-2.6%</b>	<b>98%</b>
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>12.7</b>	<b>-13.6%</b>	<b>26%</b>	<b>9.3</b>	<b>-31.7%</b>	<b>19%</b>	<b>15.0</b>	<b>+31.0%</b>	<b>31%</b>	<b>7.6</b>	<b>-45.6%</b>	<b>16%</b>	<b>44.7</b>	<b>-17.0%</b>	<b>91%</b>
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
<b>Daiichi Sankyo Europe GmbH</b>	<b>16.9</b>	<b>+14.0%</b>	<b>22%</b>	<b>16.9</b>	<b>+2.0%</b>	<b>22%</b>	<b>17.4</b>	<b>-4.3%</b>	<b>23%</b>	<b>19.1</b>	<b>+13.0%</b>	<b>25%</b>	<b>70.2</b>	<b>+5.7%</b>	<b>91%</b>
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmotec/Olmotec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
<b>Asia, South and Central America (ASCA)</b>	<b>6.5</b>	<b>+8.7%</b>	<b>22%</b>	<b>7.3</b>	<b>+3.8%</b>	<b>24%</b>	<b>6.9</b>	<b>+2.0%</b>	<b>23%</b>	<b>7.8</b>	<b>+2.8%</b>	<b>26%</b>	<b>28.6</b>	<b>+4.1%</b>	<b>95%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
<b>Ranbaxy Laboratories Limited</b>	<b>39.8</b>	<b>-27.5%</b>	<b>25%</b>	<b>38.4</b>	<b>-12.0%</b>	<b>24%</b>	<b>35.7</b>	<b>+0.6%</b>	<b>22%</b>	<b>61.6</b>	<b>+62.3%</b>	<b>38%</b>	<b>175.5</b>	<b>+2.1%</b>	<b>108%</b>
<b>Others</b>	<b>11.1</b>	<b>-38.7%</b>	<b>29%</b>	<b>9.5</b>	<b>-25.9%</b>	<b>25%</b>	<b>7.5</b>	<b>-40.5%</b>	<b>20%</b>	<b>8.8</b>	<b>-31.2%</b>	<b>23%</b>	<b>36.9</b>	<b>-34.5%</b>	<b>97%</b>
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

**[Reference] Sales in Local Currency**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
<b>Daiichi Sankyo, Inc. (US)</b>	<b>424</b>	<b>+16.1%</b>	<b>27%</b>	<b>382</b>	<b>-2.9%</b>	<b>24%</b>	<b>390</b>	<b>-7.5%</b>	<b>25%</b>	<b>412.0</b>	<b>+20.3%</b>	<b>26%</b>	<b>1,608</b>	<b>+5.6%</b>	<b>103%</b>
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>156</b>	<b>-2.8%</b>	<b>26%</b>	<b>121</b>	<b>-24.2%</b>	<b>21%</b>	<b>193</b>	<b>+36.4%</b>	<b>33%</b>	<b>96.0</b>	<b>-42.8%</b>	<b>16%</b>	<b>566</b>	<b>-10.0%</b>	<b>96%</b>
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
<b>Daiichi Sankyo Europe GmbH</b>	<b>144</b>	<b>+13.6%</b>	<b>21%</b>	<b>153</b>	<b>+2.7%</b>	<b>23%</b>	<b>165</b>	<b>+2.5%</b>	<b>25%</b>	<b>182.0</b>	<b>+21.5%</b>	<b>27%</b>	<b>644</b>	<b>+9.8%</b>	<b>96%</b>
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
<b>Ranbaxy Laboratories Limited</b>	<b>22</b>	<b>-21.5%</b>	<b>26%</b>	<b>21</b>	<b>-1.5%</b>	<b>25%</b>	<b>21</b>	<b>+8.0%</b>	<b>25%</b>	<b>38.0</b>	<b>+82.4%</b>	<b>45%</b>	<b>101</b>	<b>+13.9%</b>	<b>119%</b>

**5. Sales of Global Products (FY2011)**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
<b>Olmesartan</b>	<b>63.3</b>	<b>+5.2%</b>	<b>24%</b>	<b>60.4</b>	<b>-1.6%</b>	<b>22%</b>	<b>64.2</b>	<b>-2.3%</b>	<b>24%</b>	<b>61.7</b>	<b>+13.9%</b>	<b>23%</b>	<b>249.7</b>	<b>+3.4%</b>	<b>93%</b>
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
<b>Levofloxacin</b>	<b>13.5</b>	<b>-20.2%</b>	<b>26%</b>	<b>12.8</b>	<b>-24.1%</b>	<b>24%</b>	<b>13.9</b>	<b>-23.3%</b>	<b>26%</b>	<b>12.2</b>	<b>-29.1%</b>	<b>23%</b>	<b>52.4</b>	<b>-24.2%</b>	<b>99%</b>
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
<b>Pravastatin</b>	<b>10.2</b>	<b>-13.9%</b>	<b>27%</b>	<b>10.0</b>	<b>-15.5%</b>	<b>26%</b>	<b>10.6</b>	<b>-8.6%</b>	<b>28%</b>	<b>8.4</b>	<b>-12.6%</b>	<b>22%</b>	<b>39.2</b>	<b>-12.7%</b>	<b>103%</b>
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
<b>Prasugrel</b>	<b>2.2</b>	<b>+176.5%</b>	<b>-</b>	<b>2.3</b>	<b>+134.2%</b>	<b>-</b>	<b>2.6</b>	<b>+72.6%</b>	<b>-</b>	<b>3.8</b>	<b>+94.3%</b>	<b>-</b>	<b>10.9</b>	<b>+108.2%</b>	<b>-</b>
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Effient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

n



**1. Summary of Consolidated Income Statement (FY2010)**

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>256.4</b>	<b>+12.9%</b>	<b>100%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>100%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>100%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>100%</b>	<b>967.4</b>	<b>15.3</b>	<b>+1.6%</b>
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
<b>Operating Income</b>	<b>24%</b>	<b>61.1</b>	<b>+128.1%</b>	<b>12%</b>	<b>29.0</b>	<b>+20.6%</b>	<b>12%</b>	<b>30.5</b>	<b>-22.2%</b>	<b>1%</b>	<b>1.5</b>	<b>-72.2%</b>	<b>13%</b>	<b>122.1</b>	<b>26.6</b>	<b>+27.9%</b>
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
<b>Ordinary Income</b>	<b>27%</b>	<b>70.1</b>	<b>+877.7%</b>	<b>9%</b>	<b>22.6</b>	<b>-50.0%</b>	<b>15%</b>	<b>38.0</b>	<b>-1.1%</b>	<b>1%</b>	<b>1.2</b>	<b>-90.7%</b>	<b>14%</b>	<b>131.8</b>	<b>28.6</b>	<b>+27.8%</b>
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
<b>Net Income</b>	<b>13%</b>	<b>33.1</b>	<b>-</b>	<b>8%</b>	<b>19.1</b>	<b>-24.1%</b>	<b>11%</b>	<b>27.5</b>	<b>+33.8%</b>	<b>-4%</b>	<b>-9.5</b>	<b>-</b>	<b>7%</b>	<b>70.1</b>	<b>28.3</b>	<b>+67.5%</b>
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

**2. Currency Rate (FY2010)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02

**3. Segment Information (FY2010)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	<b>201.6</b>	<b>+2.1%</b>	100%	<b>198.8</b>	<b>-4.0%</b>	100%	<b>213.7</b>	<b>-2.4%</b>	100%	<b>181.3</b>	<b>-0.3%</b>	100%	<b>795.5</b>	<b>-10.0</b>	<b>-1.2%</b>
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
<b>Operating Income</b>	22%	<b>43.3</b>	<b>+44.0%</b>	12%	<b>23.2</b>	<b>-11.6%</b>	15%	<b>31.1</b>	<b>-20.6%</b>	1%	<b>2.3</b>	<b>-1422.3%</b>	13%	<b>99.8</b>	<b>4.6</b>	<b>+4.8%</b>
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
<b>Ordinary Income</b>	22%	<b>43.4</b>	<b>+34.8%</b>	12%	<b>23.1</b>	<b>-12.6%</b>	16%	<b>33.7</b>	<b>-12.9%</b>	0%	<b>-0.2</b>	-	13%	<b>100.0</b>	<b>3.8</b>	<b>+4.0%</b>
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
<b>Net Income</b>	11%	<b>22.3</b>	<b>+122.8%</b>	9%	<b>18.3</b>	<b>+39.4%</b>	12%	<b>26.0</b>	<b>+30.0%</b>	-4%	<b>-7.8</b>	-	7%	<b>58.8</b>	<b>23.9</b>	<b>+68.6%</b>
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	<b>54.9</b>	<b>+84.9%</b>	100%	<b>43.8</b>	<b>+20.1%</b>	100%	<b>35.5</b>	<b>-1.4%</b>	100%	<b>38.9</b>	<b>-12.6%</b>	100%	<b>173.1</b>	<b>26.4</b>	<b>+18.0%</b>
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
<b>Operating Income</b>	35%	<b>19.3</b>	<b>-1171.9%</b>	15%	<b>6.6</b>	<b>-1214.7%</b>	2%	<b>0.6</b>	<b>-60.0%</b>	3%	<b>1.1</b>	<b>-83.9%</b>	16%	<b>27.7</b>	<b>21.4</b>	<b>+338.8%</b>
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
<b>Ordinary Income</b>	52%	<b>28.3</b>	<b>-220.1%</b>	2%	<b>0.9</b>	<b>-95.4%</b>	16%	<b>5.5</b>	<b>+374.9%</b>	14%	<b>5.3</b>	<b>-65.1%</b>	23%	<b>40.0</b>	<b>27.0</b>	<b>+207.8%</b>
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
<b>Net Income</b>	33%	<b>18.4</b>	-	10%	<b>4.5</b>	<b>-68.3%</b>	11%	<b>3.8</b>	-	-9%	<b>-3.3</b>	-	14%	<b>23.3</b>	<b>19.1</b>	<b>+456.4%</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.1</b>			<b>-0.1</b>			<b>-0.1</b>			<b>-0.9</b>			<b>-1.2</b>		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
<b>Operating Income</b>		<b>-1.5</b>			<b>-0.7</b>			<b>-1.2</b>			<b>-1.9</b>			<b>-5.4</b>		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.3</b>			<b>-3.9</b>			<b>-8.2</b>		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
<b>Net Income</b>		<b>-7.6</b>			<b>-3.8</b>			<b>-2.2</b>			<b>1.6</b>			<b>-12.0</b>		



**4. Sales by Business Units (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>256.4</b>	<b>+12.9%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>967.4</b>	<b>+1.6%</b>
<b>Japan Company (domestic sales)</b>	<b>105.3</b>	<b>+0.6%</b>	<b>103.0</b>	<b>-1.7%</b>	<b>116.8</b>	<b>-1.4%</b>	<b>91.0</b>	<b>+7.6%</b>	<b>416.0</b>	<b>+0.9%</b>
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.3</b>	<b>-2.7%</b>	<b>11.7</b>	<b>-12.9%</b>	<b>13.2</b>	<b>+9.1%</b>	<b>10.6</b>	<b>+23.2%</b>	<b>44.8</b>	<b>+2.6%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.6</b>	<b>+1.7%</b>	<b>33.9</b>	<b>+1.2%</b>	<b>34.6</b>	<b>+0.6%</b>	<b>28.4</b>	<b>-11.6%</b>	<b>130.5</b>	<b>-1.9%</b>
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>14.7</b>	<b>+10.4%</b>	<b>13.7</b>	<b>+1.3%</b>	<b>11.5</b>	<b>-8.5%</b>	<b>14.0</b>	<b>+10.5%</b>	<b>53.9</b>	<b>+3.5%</b>
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
<b>Daiichi Sankyo Europe GmbH</b>	<b>14.8</b>	<b>-14.6%</b>	<b>16.6</b>	<b>-10.0%</b>	<b>18.1</b>	<b>-5.0%</b>	<b>16.9</b>	<b>-17.2%</b>	<b>66.4</b>	<b>-11.7%</b>
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
<b>Asia, South and Central America (ASCA)</b>	<b>5.9</b>	<b>+12.7%</b>	<b>7.1</b>	<b>+12.8%</b>	<b>6.8</b>	<b>+3.3%</b>	<b>7.6</b>	<b>-0.4%</b>	<b>27.4</b>	<b>+6.4%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
<b>Ranbaxy Laboratories Limited</b>	<b>54.8</b>	<b>+84.7%</b>	<b>43.7</b>	<b>+19.9%</b>	<b>35.4</b>	<b>-1.6%</b>	<b>38.0</b>	<b>-14.5%</b>	<b>171.9</b>	<b>+17.3%</b>
<b>Others</b>	<b>18.0</b>	<b>+25.6%</b>	<b>12.8</b>	<b>-25.1%</b>	<b>12.7</b>	<b>-20.2%</b>	<b>12.8</b>	<b>-20.0%</b>	<b>56.3</b>	<b>-11.1%</b>
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

**[Reference] Sales in Local Currency (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daiichi Sankyo, Inc. (US)</b>	<b>365</b>	<b>+7.6%</b>	<b>394</b>	<b>+10.2%</b>	<b>422</b>	<b>+10.3%</b>	<b>342</b>	<b>-3.3%</b>	<b>1,522</b>	<b>+6.3%</b>
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>160</b>	<b>+16.7%</b>	<b>159</b>	<b>+10.6%</b>	<b>142</b>	<b>+1.2%</b>	<b>168</b>	<b>+20.1%</b>	<b>629</b>	<b>+12.1%</b>
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
<b>Daiichi Sankyo Europe GmbH</b>	<b>126</b>	<b>-3.2%</b>	<b>149</b>	<b>+8.3%</b>	<b>161</b>	<b>+12.1%</b>	<b>150</b>	<b>-7.0%</b>	<b>587</b>	<b>+2.3%</b>
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>28</b>	<b>+76.3%</b>	<b>21</b>	<b>+17.1%</b>	<b>19</b>	<b>+4.6%</b>	<b>21</b>	<b>-9.0%</b>	<b>89</b>	<b>+18.5%</b>

**5. Sales of Global Products (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmesartan</b>	<b>60.2</b>	<b>+7.6%</b>	<b>61.4</b>	<b>+3.4%</b>	<b>65.7</b>	<b>+1.6%</b>	<b>54.2</b>	<b>-7.0%</b>	<b>241.5</b>	<b>+1.4%</b>
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
<b>Levofloxacin</b>	<b>17.0</b>	<b>-14.3%</b>	<b>16.9</b>	<b>-28.0%</b>	<b>18.1</b>	<b>-18.3%</b>	<b>17.2</b>	<b>-21.1%</b>	<b>69.1</b>	<b>-20.7%</b>
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
<b>Pravastatin</b>	<b>11.9</b>	<b>-19.1%</b>	<b>11.8</b>	<b>-21.5%</b>	<b>11.6</b>	<b>-21.8%</b>	<b>9.6</b>	<b>-8.3%</b>	<b>44.9</b>	<b>-18.4%</b>
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.8</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>1.5</b>	<b>-</b>	<b>2.0</b>	<b>-</b>	<b>5.2</b>	<b>+889.6%</b>
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

**1. Summary of Consolidated Income Statement (FY2009)**

JPY Bn	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>227.1</b>	<b>+11.5%</b>	<b>100%</b>	<b>243.4</b>	<b>+20.2%</b>	<b>100%</b>	<b>255.1</b>	<b>+15.3%</b>	<b>100%</b>	<b>226.4</b>	<b>+5.6%</b>	<b>100%</b>	<b>952.1</b>	<b>110.0</b>	<b>+13.1%</b>
Cost of sales	28%	62.5	+28.5%	31%	74.7	+52.5%	30%	75.4	+41.9%	29%	65.4	+2.8%	29%	278.0	63.6	+29.7%
Gross Profit	72%	164.6	+6.1%	69%	168.7	+9.8%	70%	179.7	+6.8%	71%	161.1	+6.7%	71%	674.1	46.3	+7.4%
SG&A expenses	61%	137.8	+19.8%	59%	144.6	+9.6%	55%	140.5	+6.6%	69%	155.6	-2.8%	61%	578.6	39.7	+7.4%
R&D expenses	20%	45.1	+22.2%	20%	49.0	+7.9%	19%	47.6	+1.6%	24%	55.1	-0.5%	21%	196.8	12.3	+6.6%
Other expenses	41%	92.7	+18.6%	39%	95.6	+10.5%	36%	92.9	+9.4%	44%	100.5	-4.0%	40%	381.8	27.4	+7.7%
<b>Operating Income</b>	<b>12%</b>	<b>26.8</b>	<b>-33.1%</b>	<b>10%</b>	<b>24.1</b>	<b>+11.5%</b>	<b>15%</b>	<b>39.2</b>	<b>+7.6%</b>	<b>2%</b>	<b>5.4</b>	<b>-</b>	<b>10%</b>	<b>95.5</b>	<b>6.6</b>	<b>+7.5%</b>
Non-operating income / expenses		-19.6			21.0			-0.8			7.0			7.6	41.3	
Non-operating income		3.9			10.9			4.3			9.1			28.2	15.9	
Non-operating expenses		23.5			-10.1			5.1			2.1			20.6	-25.4	
<b>Ordinary Income</b>	<b>3%</b>	<b>7.2</b>	<b>-82.5%</b>	<b>19%</b>	<b>45.1</b>	<b>+140.0%</b>	<b>15%</b>	<b>38.4</b>	<b>+14.4%</b>	<b>6%</b>	<b>12.5</b>	<b>-</b>	<b>11%</b>	<b>103.1</b>	<b>47.9</b>	<b>+86.9%</b>
Extraordinary income / losses		1.5			-0.1			-1.1			-6.1			-5.7	357.7	
Extraordinary income		2.1			0.2			1.5			2.1			5.9	2.1	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-355.6	
Income before income taxes and minority interests	4%	8.6	-78.2%	18%	45.0	+164.3%	15%	37.3	-	3%	6.4	-	10%	97.4	405.6	-
Income taxes / minority interests		15.1			19.9			16.8			3.8			55.5	148.3	
Income taxes		24.0			12.8			16.0			-2.7			50.0	129.2	
Minority interests		-8.9			7.1			0.7			6.5			5.5	19.1	
<b>Net Income</b>	<b>-3%</b>	<b>-6.4</b>	<b>-</b>	<b>10%</b>	<b>25.1</b>	<b>+182.7%</b>	<b>8%</b>	<b>20.6</b>	<b>-</b>	<b>1%</b>	<b>2.6</b>	<b>-96.8%</b>	<b>4%</b>	<b>41.9</b>	<b>257.4</b>	<b>-</b>
Effective tax rate		278%			28%			43%			-			51%		
Overseas sales ratio results		48%			50%			47%			57%			51%		

**2. Currency Rate (FY2009)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2009	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	97.33	95.50	93.57	92.86	92.86	-7.68
EUR/JPY (average)	132.58	133.16	133.00	131.16	131.16	-12.33
INR/JPY (average)	1.89	1.95	1.95	1.95	1.95	-0.05

**3. Segment Information (FY2009)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	197.4	-3.1%	100%	207.0	+2.2%	100%	219.1	-1.0%	100%	181.9	+3.4%	100%	805.5	1.9	+0.2%
Cost of sales	23%	45.4	-6.7%	26%	54.3	+10.9%	25%	55.6	+4.6%	26%	47.3	+14.6%	25%	202.6	10.5	+5.5%
Gross Profit	77%	152.0	-2.0%	74%	152.7	-0.6%	75%	163.5	-2.8%	74%	134.6	+0.0%	75%	602.8	-8.6	-1.4%
SG&A expenses	62%	122.0	+6.0%	61%	126.5	-4.2%	57%	124.3	-1.5%	74%	134.8	+3.3%	63%	507.6	3.8	+0.8%
R&D expenses	22%	43.0	+16.5%	23%	46.7	+2.8%	21%	45.2	-3.5%	28%	51.6	+12.4%	23%	186.5	11.4	+6.5%
Other expenses	40%	79.0	+1.1%	39%	79.8	-7.8%	36%	79.1	-0.3%	46%	83.2	-1.7%	40%	321.1	-7.7	-2.3%
<b>Operating Income</b>	15%	30.0	-24.9%	13%	26.2	+21.3%	18%	39.1	-6.7%	0%	-0.2	-	12%	95.2	-12.4	-11.5%
Non-operating income		2.9			2.0			1.8			0.4			7.1	-3.8	
Non-operating expenses		0.8			1.8			2.2			1.4			6.1	-13.9	
<b>Ordinary Income</b>	16%	32.2	-21.3%	13%	26.4	+40.5%	18%	38.7	-0.8%	-1%	-1.1	-	12%	96.1	-2.2	-2.3%
Extraordinary income		2.1			0.2			1.5			0.8			4.6	0.9	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-4.0	
Income before income taxes and minority interests	17%	33.6	-15.0%	13%	26.3	+54.4%	17%	37.7	+0.5%	-5%	-8.5	-	11%	89.1	2.7	+3.2%
Income taxes		23.6			13.1			17.7			-0.2			54.3	17.8	
Minority interests																
<b>Net Income</b>	5%	10.0	-60.1%	6%	13.2	+48.0%	9%	20.0	-27.9%	-5%	-8.3	-	4%	34.8	-15.1	-30.2%
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	29.7		100%	36.4		100%	36.0		100%	44.5	+15.1%	100%	146.7	108.0	
Cost of sales	58%	17.1		56%	20.4		55%	19.8		41%	18.1	-12.0%	51%	75.4	54.9	
Gross Profit	42%	12.6		44%	16.0		45%	16.2		59%	26.4	+45.8%	49%	71.2	53.1	
SG&A expenses	48%	14.4		46%	16.6		41%	14.6		43%	19.3	+10.0%	44%	64.9	47.4	
R&D expenses	7%	2.1		6%	2.3		7%	2.4		8%	3.5	+35.7%	7%	10.3	7.7	
Other expenses	41%	12.3		39%	14.3		34%	12.2		36%	15.8	+5.6%	37%	54.6	39.6	
<b>Operating Income</b>	-6%	-1.8		-2%	-0.6		4%	1.6		16%	7.1	+1119.4%	4%	6.3	5.7	
Non-operating income		1.0			9.0			2.5			8.7			21.1	19.7	
Non-operating expenses		22.7			-11.9			2.9			0.7			14.5	-11.5	
<b>Ordinary Income</b>	-79%	-23.5		56%	20.2		3%	1.2		34%	15.1	-	9%	13.0	36.9	
Extraordinary income		0.0			0.0			0.0			1.3			1.3	1.2	
Extraordinary losses								0.0			0.1			0.1	-0.2	
Income before income taxes and minority interests	-79%	-23.5		56%	20.2		3%	1.1		37%	16.4	-	10%	14.2	38.3	
Income taxes		-6.6			6.0			1.3			9.2			9.8	17.7	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.1	
<b>Net Income</b>	-57%	-16.9		39%	14.2		-1%	-0.2		16%	7.1	-	3%	4.2	20.4	
<b>Inter-segment Transactions</b>																
<b>Net sales</b>																
Cost of sales																
Gross Profit																
SG&A expenses		1.5			1.5			1.5			1.5			6.0		
R&D expenses																
Other expenses		1.5			1.5			1.5			1.5			6.0		
<b>Operating Income</b>		-1.5			-1.5			-1.5			-1.5			-6.0		
Non-operating income																
Non-operating expenses																
<b>Ordinary Income</b>		-1.5			-1.5			-1.5			-1.5			-6.0		
Extraordinary income																
Extraordinary losses																
Income before income taxes and minority interests		-1.5			-1.5			-1.5			-1.5			-6.0		
Income taxes		7.0			-6.4			-3.0			-11.8			-14.1		
Minority interests		-8.9			7.1			0.7			6.5			5.3		
<b>Net Income</b>		0.5			-2.3			0.8			3.8			2.8		

**4. Sales by Business Units (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>227.1</b>	<b>11.5%</b>	<b>243.4</b>	<b>20.2%</b>	<b>255.1</b>	<b>15.3%</b>	<b>226.4</b>	<b>5.6%</b>	<b>952.1</b>	<b>13.1%</b>
<b>Japan Company (domestic sales)</b>	<b>104.6</b>	<b>3.7%</b>	<b>104.8</b>	<b>5.3%</b>	<b>118.4</b>	<b>-1.4%</b>	<b>84.5</b>	<b>-1.9%</b>	<b>412.3</b>	<b>1.4%</b>
Olmotec	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Calblock	3.5	14.5%	3.5	18.9%	3.8	12.5%	2.9	4.7%	13.7	12.8%
Loxonin	11.2	33.0%	12.5	19.7%	13.3	16.0%	9.9	19.4%	47.0	21.4%
Cravit	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Mevalotin	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Artist	6.0	6.3%	5.9	11.3%	6.4	6.0%	5.0	1.9%	23.3	6.5%
Omnipaque	7.1	-2.0%	7.5	3.4%	7.1	-10.8%	5.5	-4.8%	27.3	-3.7%
Urief	2.2	26.6%	2.2	26.1%	2.6	19.3%	2.0	-9.9%	9.0	14.3%
Vaccines	1.3	235.0%	1.9	40.4%	8.6	22.9%	1.3	151.5%	13.1	41.0%
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.5</b>	<b>-6.9%</b>	<b>13.5</b>	<b>-2.1%</b>	<b>12.1</b>	<b>-8.2%</b>	<b>8.6</b>	<b>-14.1%</b>	<b>43.7</b>	<b>-7.4%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.0</b>	<b>-11.2%</b>	<b>33.5</b>	<b>5.6%</b>	<b>34.4</b>	<b>5.8%</b>	<b>32.1</b>	<b>15.2%</b>	<b>133.0</b>	<b>2.9%</b>
Olmесartan	25.1	1.5%	25.4	3.5%	26.4	5.9%	24.9	13.6%	101.7	5.9%
Benicar/Benicar HCT	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Welchol	6.9	7.0%	6.5	6.6%	7.3	10.2%	6.8	28.2%	27.5	12.4%
Effient (alliance revenue)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>13.4</b>	<b>-1.1%</b>	<b>13.5</b>	<b>-0.4%</b>	<b>12.6</b>	<b>-6.4%</b>	<b>12.7</b>	<b>18.9%</b>	<b>52.1</b>	<b>1.9%</b>
Venofer	8.0	-3.9%	8.1	-4.6%	8.0	-4.1%	8.0	17.0%	32.2	0.3%
<b>Daiichi Sankyo Europe GmbH</b>	<b>17.3</b>	<b>14.1%</b>	<b>18.4</b>	<b>-0.4%</b>	<b>19.1</b>	<b>6.1%</b>	<b>20.4</b>	<b>9.7%</b>	<b>75.2</b>	<b>7.1%</b>
Olmесartan	9.2	10.7%	11.2	7.9%	12.4	17.9%	13.5	28.3%	46.3	16.5%
Olmotec/Olmotec Plus	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
<b>Asia, South and Central America (ASCA)</b>	<b>5.3</b>	<b>0.5%</b>	<b>6.3</b>	<b>7.1%</b>	<b>6.6</b>	<b>11.7%</b>	<b>7.7</b>	<b>27.5%</b>	<b>25.8</b>	<b>12.1%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.0	-4.3%	1.1	7.6%	1.1	3.1%	0.9	1.4%	4.1	2.0%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.1	48.0%	1.3	40.2%	1.4	35.2%	1.5	34.0%	5.3	38.4%
Daiichi Sankyo Taiwan	0.9	-8.6%	0.8	-14.9%	0.7	-14.4%	0.7	-4.5%	3.1	-10.7%
Daiichi Sankyo Korea	0.8	-15.6%	0.9	-2.1%	0.9	56.8%	0.9	38.9%	3.4	13.7%
Daiichi Sankyo (Thailand)	0.2	-0.9%	0.2	-0.4%	0.2	4.2%	0.3	27.4%	0.9	7.7%
Daiichi Sankyo Brasil Farmacêutica	0.8	-25.5%	1.0	-12.7%	1.3	-7.2%	1.6	18.4%	4.7	-5.2%
Daiichi Sankyo Venezuela	0.7	35.3%	0.9	45.0%	0.8	20.7%	1.7	76.3%	4.1	47.9%
<b>Ranbaxy Laboratories Limited</b>	<b>29.7</b>	<b>-</b>	<b>36.4</b>	<b>-</b>	<b>36.0</b>	<b>-</b>	<b>44.4</b>	<b>14.9%</b>	<b>146.6</b>	<b>-</b>
<b>Others</b>	<b>14.4</b>	<b>-33.2%</b>	<b>17.1</b>	<b>-13.6%</b>	<b>15.9</b>	<b>-12.3%</b>	<b>16.0</b>	<b>-3.0%</b>	<b>63.4</b>	<b>-16.5%</b>
Levofloxacin export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Efient alliance revenue (Europe)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-



**[Reference] Sales in Local Currency (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daiichi Sankyo, Inc. (US)</b>	<b>339</b>	<b>-4.6%</b>	<b>357</b>	<b>21.7%</b>	<b>382</b>	<b>13.4%</b>	<b>354</b>	<b>18.0%</b>	<b>1,433</b>	<b>11.4%</b>
Olmесartan	258	9.0%	271	18.9%	293	13.9%	274	16.9%	1,095	14.6%
Benicar/Benicar HCT	227	1.4%	237	15.6%	253	9.7%	242	14.8%	958	10.2%
Azor	31	138.0%	34	49.3%	40	50.9%	32	35.4%	138	59.4%
Welchol	71	14.9%	69	22.8%	81	18.7%	75	31.4%	296	21.7%
Effient (alliance revenue)	-	-	10	-	2	-	-11	-	1	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>137</b>	<b>6.2%</b>	<b>144</b>	<b>14.5%</b>	<b>140</b>	<b>1.1%</b>	<b>140</b>	<b>21.4%</b>	<b>561</b>	<b>10.3%</b>
Venofer	82	3.2%	87	9.6%	89	3.3%	89	19.8%	346	8.6%
EUR Mn										
<b>Daiichi Sankyo Europe GmbH</b>	<b>131</b>	<b>40.6%</b>	<b>138</b>	<b>20.8%</b>	<b>144</b>	<b>5.9%</b>	<b>161</b>	<b>9.8%</b>	<b>574</b>	<b>17.1%</b>
Olmесartan	69	36.4%	83	30.9%	93	18.4%	106	28.1%	353	27.5%
Olmotec/Olmotec Plus	63	23.0%	74	16.7%	77	10.6%	90	17.2%	304	16.5%
Sevikar	7	-	9	-	16	77.6%	16	166.6%	48	216.5%
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>16</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>23</b>	<b>17.9%</b>	<b>75</b>	<b>-</b>

**5. Sales of Global Products (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmесartan</b>	<b>56.0</b>	<b>10.5%</b>	<b>59.4</b>	<b>10.2%</b>	<b>64.7</b>	<b>12.3%</b>	<b>58.3</b>	<b>19.0%</b>	<b>238.3</b>	<b>12.9%</b>
Olmotec (JPN)	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Benicar/Benicar HCT (US)	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor (US)	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Olmotec/Olmotec Plus (EU)	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar (EU)	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Other subsidiaries, export, etc	2.6	29.9%	3.1	-7.8%	3.7	6.2%	3.7	71.4%	13.1	19.2%
<b>Levofloxacin</b>	<b>19.8</b>	<b>-23.2%</b>	<b>23.5</b>	<b>-0.3%</b>	<b>22.1</b>	<b>-14.2%</b>	<b>21.8</b>	<b>-3.5%</b>	<b>87.2</b>	<b>-10.7%</b>
Cravit (JPN)	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Other subsidiaries	1.8	-6.4%	2.0	2.9%	2.1	14.7%	1.8	-2.2%	7.7	2.2%
<b>Pravastatin</b>	<b>14.7</b>	<b>-8.5%</b>	<b>15.0</b>	<b>-5.2%</b>	<b>14.8</b>	<b>-10.8%</b>	<b>10.5</b>	<b>-14.9%</b>	<b>55.0</b>	<b>-9.6%</b>
Mevalotin (JPN)	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Other subsidiaries, export, etc	2.3	-10.0%	2.6	-6.5%	2.0	-20.2%	2.0	-15.7%	8.8	-12.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.0</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>0.3</b>	<b>-</b>	<b>-0.7</b>	<b>-</b>	<b>0.5</b>	<b>-</b>
Effient alliance revenue (US)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Efient alliance revenue (EU)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-